Top

Published in:

01-03-2015 | Original Paper

Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor

Authors: Arnt V. Kristen, Johannes Rinn, Ute Hegenbart, David Lindenmaier, Corina Merkle, Christoph Röcken, Stefan Hardt, Evangelos Giannitsis, Hugo A. Katus

Published in: Clinical Research in Cardiology | Issue 3/2015

Abstract

Background

Vascular amyloid deposition is common in light-chain amyloidosis resulting in endothelial dysfunction. Human placental growth factor (PlGF), a member of the vascular endothelial growth factor family was found to be altered in diverse pathological conditions, e.g. endothelial dysfunction. This study evaluated the clinical role of PlGF in light-chain amyloidosis.

Methods

PlGF (cobas-PlGF, Roche Diagnostics, Mannheim, Germany) was analyzed in 125 consecutive patients with AL and correlated with diverse clinical parameters including mortality.

Results

Kidney (n = 76) and heart (n = 57) were predominantly affected by amyloid deposition. Median PlGF was 26.3 (21.1–42.1) ng/L, NT-proBNP 3649 (1124–8581) pg/mL, and hs-TnT 42 (21–107) ng/L. PlGF increased with number of organs involved and with deterioration of renal function. A significant correlation of PlGF with hs-TnT (ρ = 0.306; p = 0.0007) and NT-proBNP (ρ = 0.315; p = 0.0006) was observed, but no correlation was observed with clinical, echocardiography, and electrocardiography parameters of cardiac involvement. In this cohort 1-year all-cause mortality was 19.2 %. The best cutoff discriminating survivors and non-survivors was 28.44 ng/L (sensitivity 66.7 %; specificity 78.1 %). A three-step risk model including hs-TnT and NT-proBNP revealed a better discrimination if patients at intermediary risk were additionally stratified by PlGF. Net reclassification index was 37.2 % (p = 0.002). Multivariate analysis revealed PlGF, difference of involved and uninvolved light chain, number of organs involved and risk class according to troponin T and NT-proBNP as independent predictors of mortality.

Conclusion

Plasma PlGF values in AL are invariably associated with the number of involved organs, but not with clinical, echocardiography, and electrocardiography parameters of cardiac involvement. PlGF provide useful information for risk stratification of patients at intermediary risk according to hs-TnT and NT-proBNP.

Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78:74–82CrossRefPubMedCentralPubMed

Kristen AV, Perz JB, Schonland SO et al (2007) Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 26:1313–1319CrossRefPubMed

Palladini G, Malamani G, Co F et al (2001) Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 24:1228–1233CrossRefPubMed

Cueto-Garcia L, Reeder GS, Kyle RA et al (1985) Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 6:737–743CrossRefPubMed

Koyama J, Ray Sequin PA, Falk RH (2002) Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation 106:556–561CrossRefPubMed

Kristen AV, Perz J, Schonland S et al (2007) Non-invasive Predictors of Survival in Cardiac Amyloidosis. Eur J Heart Fail 9:617–624CrossRefPubMed

Buss SJ, Mereles D, Emami M et al (2012) Rapid assessment of longitudinal systolic left ventricular function using speckle tracking of the mitral annulus. Clin Res Cardiol 101:273–280CrossRefPubMed

Dispenzieri A, Kyle RA, Gertz MA et al (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361:1787–1789CrossRefPubMed

Palladini G, Campana C, Klersy C et al (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440–2445CrossRefPubMed

10.

Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751–3757CrossRefPubMed

11.

Brunner H, Cockcroft JR, Deanfield J et al (2005) Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23:233–246CrossRefPubMed

12.

Crotty TB, Chin-Yang L, Edwards WD, Suman VJ (1995) Amyloidosis and endomyocardial biopsy: correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol 4:39–42CrossRef

13.

Modesto KM, Dispenzieri A, Gertz M et al (2007) Vascular abnormalities in primary amyloidosis. Eur Heart J 28:1019–1024CrossRefPubMed

14.

Al Suwaidi J, Velianou JL, Gertz MA et al (1999) Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 131:838–841CrossRefPubMed

15.

Berghoff M, Kathpal M, Khan F et al (2003) Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Ann Neurol 53:725–730CrossRefPubMed

16.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ (2010) Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 122:478–487CrossRefPubMed

17.

Persico MG, Vincenti V, DiPalma T (1999) Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 237:31–40PubMed

18.

Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62:179–213CrossRefPubMed

19.

Tarnow L, Astrup AS, Parving HH (2005) Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Scand J Clin Lab Invest Suppl 240:73–79CrossRefPubMed

20.

Cianfarani F, Zambruno G, Brogelli L et al (2006) Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol 169:1167–1182CrossRefPubMedCentralPubMed

21.

Heeschen C, Dimmeler S, Fichtlscherer S et al (2004) Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291:435–441CrossRefPubMed

22.

Lenderink T, Heeschen C, Fichtlscherer S et al (2006) Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 47:307–311CrossRefPubMed

23.

Luttun A, Tjwa M, Moons L et al (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:831–840PubMed

24.

Iyer S, Acharya KR (2002) Role of placenta growth factor in cardiovascular health. Trends Cardiovasc Med 12:128–134CrossRefPubMed

25.

Beck H, Acker T, Puschel AW et al (2002) Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J Neuropathol Exp Neurol 61:339–350PubMed

26.

Schonland SO, Hegenbart U, Bochtler T et al (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119:488–493CrossRefPubMed

27.

Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470CrossRefPubMed

28.

Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10(th) International Symposium on Amyloid and Amyloidosis. Am J Hematol 79:319–328CrossRefPubMed

29.

Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328CrossRefPubMed

30.

Rahman JE, Helou EF, Gelzer Bell R et al (2004) Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43:410–415CrossRefPubMed

31.

Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458CrossRefPubMed

32.

Giannitsis E, Kurz K, Hallermayer K et al (2010) Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 56:254–261CrossRefPubMed

33.

Kurz K, Giannitsis E, Zehelein J, Katus HA (2008) Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. Clin Chem 54:1234–1238CrossRefPubMed

34.

Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172CrossRefPubMed

35.

Ukena C, Kindermann M, Mahfoud F et al (2014) Diagnostic and prognostic validity of different biomarkers inpatients with suspected myocarditis. Clin Res Cardiol 103(9):743–751CrossRefPubMed

36.

Leistner DM, Klotsche J, Pieper L et al (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 102(4):259–268CrossRefPubMed

37.

Behnes M, Brueckmann M, Lang S et al (2014) Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure. Clin Res Cardiol 103(2):107–116CrossRefPubMed

38.

Mattei MG, Borg JP, Rosnet O, Marme D, Birnbaum D (1996) Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12–p21 and 14q24–q31 regions, respectively. Genomics 32:168–169CrossRefPubMed

39.

Autiero M, Luttun A, Tjwa M, Carmeliet P (2003) Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1:1356–1370CrossRefPubMed

40.

Nakamura T, Funayama H, Kubo N et al (2009) Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol 131:186–191CrossRefPubMed

41.

Lenderink T, Heeschen C, Fichtlscherer S et al (2006) Elevated placental growth factor levels are associated with adverse outcomes at 4-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 47:307–311CrossRefPubMed

42.

Iwama H, Uemura S, Naya N et al (2006) Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 47:1559–1567CrossRefPubMed

43.

Brenner DA, Jain M, Pimentel DR et al (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94:1008–1010CrossRefPubMed

44.

Liao R, Jain M, Teller P et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104:1594–1597PubMed

45.

Dispenzieri A, Gertz MA, Kyle RA et al (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881–1887CrossRefPubMed

46.

Kristen AV, Lehrke S, Buss S et al (2012) Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 101:805–813CrossRefPubMedCentralPubMed

Title: Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor
Authors: Arnt V. Kristen
Johannes Rinn
Ute Hegenbart
David Lindenmaier
Corina Merkle
Christoph Röcken
Stefan Hardt
Evangelos Giannitsis
Hugo A. Katus
Publication date: 01-03-2015
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 3/2015
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-014-0779-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleep-disordered breathing: a meta-analysis

Percutaneous mitral valve repair as rescue procedure after post myocardial infarction papillary muscle rupture and acute cardiogenic shock

Effects of β-blocker therapy on electrocardiographic and echocardiographic characteristics of left ventricular noncompaction

Elevated M2-muscarinic and β1-adrenergic receptor autoantibody levels are associated with paroxysmal atrial fibrillation

Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options

Successful single-sided renal denervation in drug-resistant hypertension and ventricular tachycardia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page